A Guide to Integrating Emerging Therapies into Current Treatment Paradigms for Hepatocellular Carcinoma

A Guide to Integrating Emerging Therapies into Current Treatment Paradigms for Hepatocellular Carcinoma

Live Webinar
Date Time
Wednesday, August 22, 2018 1:30pm to 2:30pm ET Register
Wednesday, August 29, 2018 2:30pm to 3:30pm ET Register
Faculty

Program Chair
Ghassan Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Panelists

Anne M. Covey, MD
Professor of Radiology
Weill Cornell Medical Center
Attending Radiologist
Memorial Sloan Kettering Cancer Center
New York, New York

Constantino Peña, MD
Medical Director, Vascular Imaging
Interventional Radiology
Miami Cardiac & Vascular Institute
Voluntary Clinical Assistant Professor, Radiology
Florida International University, Herbert Wertheim College of Medicine
Affiliate Assistant Professor, Radiology
University of South Florida College of Medicine
Miami, Florida

Natasha A. Pinheiro, MSN, NP, AGPCNP-BC, AOCNS®
Nurse Practitioner, GI Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Amit Singal, MD
Medical Director, Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Intended Learners

This activity is designed for medical, radiological and surgical oncologists, gastroenterologists, and hepatologists.

Learning Objectives

At the completion of this activity, the participant will be better able to:

  • Discuss emerging agents, including immune checkpoint inhibitor therapies, that enhance survival for patients with HCC who have disease progression after sorafenib
  • Evauate PK-PD profiles, efficacy, and adverse event data that are emerging regarding newer TKIs and IO agents as monotherapy and/or in combination for management of HCC
  • Interpret recent results and ongoing clinical trials pertaining to therapeutic strategies designed to improve patients' outcomes in HCC
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Provider


This activity is provided by Imedex®, LLC.

 

Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and NACCME. Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designated this live activity for a maximum of 1 AMA PRA Category 1 CreditTM.

Planning Committee

The planning committee comprises Ghassan K. Abou-Alfa, MD, MBA; Anne Covey, MD; Constantino Pena, MD; Natasha A. Pinheiro, MSN, NP, AGPCNP-BC, AOCNS®; Robert S. Dieter, MD, RVT, FACC; Susie Seaman, NP; Monalisa Singh, MD, PhD, and Susan Yarbrough, Imedex; and Kristin Ciszeski, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, and Randy Robbin, NACCME.

Independent Clinical Reviewer: Robert S. Dieter, MD, RVT, FACC, Loyola University Medicine, Chicago, Illinois 

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Abou-Alfa: Grant/Research Support --  Agios, Array, Astra Zeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche; Consulting -- Agios, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, BMS, Boston Scientifc, Carsgen, Celgene, Casi, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Vicus, Yakult

Dr. Covey:  Advisory Board -- Guerbet; Major Stock Shareholder -- Amgen, Guerbet

Dr. Peña: Consultant -- Boston Scientific, CR Bard, Halyard, Medtronic, WL Gore; Speakers’ Burearu- Boston Scientific, BTG, Cook Inc, CR Bard, Medtronic, Merit, Penumbra, Terumo

Dr. Singal: TBD

Dr. Dieter, Ms. Pinheiro, Monalisa Singh, Susan Yarbrough, Kristin Ciszeski, MaryEllen Fama, Emily Gibson, Jennifer Ilcyn, and Randy Robbin  have disclosed no relevant financial relationships with any commercial interests.

Privacy Policy

NACCME and Imedex protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex  maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by Imedex, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Imedex. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or Imedex . Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc .

 

.